Strange DNA structures may drive cancer development
LJI researchers shed light on the role of TET enzymes in genomic stability and cancers
Six LJI scientists named “Highly Cited Researchers”
The international recognition reflects how LJI research is valued by scientific peers
Immune cells can detect cancer
Now we can see what they see — and help
Preparing T cells for the long haul
New LJI research could keep cancer-fighting T cells from burning out before the job is done
Hard-working enzyme keeps immune cells in line
LJI scientists develop new tool for understanding enzymatic activity linked to blood cancers and heart disease
Many cancer patients may need a sequential one-two punch of immunotherapies
Treating patients with anti-CTLA4 therapies prior to anti-PD1 treatment may be a promising strategy
LJI launches new global cancer immunology resource
National Cancer Institute support brings cancer researchers together to share key findings
Amnon Altman: Leading immunologist and educator retires
Dr. Altman’s research into T cell activation opened the door to new therapies for inflammation, autoimmune diseases, cancers, and more.
Cancer Immunology
In 2013, Dr. Vijayanand teamed up with Professor Christian Ottensmeier at the Cancer Center, University of Southampton, UK, to
A clue to how some fast-growing tumors hide in plain sight
New LJI research could guide the development of more effective cancer immunotherapies
Proteomics expert Sam Myers to join LJI faculty
Myers Lab to expand autoimmune disease research, cancer and more
Klaus Ley Receives $2.3 Million to Study Fundamentals of Immune Cell Activation
LA JOLLA—Scientists at La Jolla Institute for Immunology (LJI) have received a new grant of more than $2.3 million from the National